136.99
price up icon1.16%   1.57
after-market After Hours: 136.99
loading
Neurocrine Biosciences Inc stock is traded at $136.99, with a volume of 1.30M. It is up +1.16% in the last 24 hours and up +9.03% over the past month. Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
See More
Previous Close:
$135.42
Open:
$135.37
24h Volume:
1.30M
Relative Volume:
1.38
Market Cap:
$13.87B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
73.65
EPS:
1.86
Net Cash Flow:
$440.10M
1W Performance:
+2.96%
1M Performance:
+9.03%
6M Performance:
+1.80%
1Y Performance:
+6.65%
1-Day Range:
Value
$132.83
$137.11
1-Week Range:
Value
$132.10
$140.00
52-Week Range:
Value
$110.95
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
1,700
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
136.99 13.87B 2.24B 385.90M 440.10M 3.73
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
164.28 74.12B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.72 43.95B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.17 41.75B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
22.21 25.17B 16.77B -959.00M 1.37B -0.85
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
12.49 14.91B 15.05B -883.30M 1.89B -0.74

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-10-24 Resumed Raymond James Outperform
Aug-29-24 Upgrade Piper Sandler Neutral → Overweight
Apr-24-24 Upgrade Wells Fargo Equal Weight → Overweight
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
02:55 AM

Neurocrine Biosciences, Inc. Selects PANTHERx®Rare Specialty Pharmacy for Distribution of Crenessity™ (crinecerfont) - StreetInsider.com

02:55 AM
pulisher
10:31 AM

Neurocrine Biosciences (NASDAQ:NBIX) Given "Overweight" Rating at Piper Sandler - MarketBeat

10:31 AM
pulisher
08:11 AM

Barclays Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat

08:11 AM
pulisher
04:19 AM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Sanctuary Advisors LLC - MarketBeat

04:19 AM
pulisher
Dec 21, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 21, 2024
pulisher
Dec 20, 2024

BofA raises Neurocrine Bio target to $182 on drug launch By Investing.com - Investing.com Canada

Dec 20, 2024
pulisher
Dec 20, 2024

What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter

Dec 20, 2024
pulisher
Dec 20, 2024

Needham & Company LLC Reaffirms "Hold" Rating for Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine launches CRENESSITY for adrenal hyperplasia in US By Investing.com - Investing.com South Africa

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Bioscience’s CRENESSITY Becomes Commercially Available In The U.S. - Contract Pharma

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Biosciences (NBIX) Announces Commercial Availability of CRENESSITY for Children and Adults With Classic Congenital Adrenal Hyperplasia - StreetInsider.com

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine launches CRENESSITY for adrenal hyperplasia in US - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PR Newswire

Dec 20, 2024
pulisher
Dec 19, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 1,091 Shares - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Neurocrine Biosciences chief regulatory officer sells $147,285 in shares - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Neurocrine Biosciences chief regulatory officer sells $147,285 in shares By Investing.com - Investing.com UK

Dec 19, 2024
pulisher
Dec 18, 2024

Neurocrine Biosciences' SWOT analysis: stock outlook mixed amid pipeline setbacks - Investing.com Canada

Dec 18, 2024
pulisher
Dec 18, 2024

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth - Seeking Alpha

Dec 18, 2024
pulisher
Dec 18, 2024

Tidal Investments LLC Acquires 5,197 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

HighTower Advisors LLC Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Neurocrine wins FDA OK for first-in-class CAH drug - The Pharma Letter

Dec 17, 2024
pulisher
Dec 17, 2024

Franklin Resources Inc. Sells 144,114 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

FDA Tracker: Neurocrine, Checkpoint Score FDA Approvals - BioSpace

Dec 17, 2024
pulisher
Dec 17, 2024

Neurocrine’s First New CAH Treatment in 70 Years Gets FDA Approval - geneonline

Dec 17, 2024
pulisher
Dec 16, 2024

Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder - MedCity News

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years - News & Insights

Dec 16, 2024
pulisher
Dec 16, 2024

Blockbuster bound? Neurocrine’s hyperplasia drug approved - BioWorld Online

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug - Yahoo! Voices

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Trading 5% HigherHere's What Happened - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Novo builds up manufacturing; Pepgen Duchenne trial put on hold - BioPharma Dive

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences rises on FDA nod for CAH drug By Investing.com - Investing.com Australia

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences rises on FDA nod for CAH drug - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Receives "Outperform" Rating from William Blair - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

FDA clears Neurocrine drug for rare adrenal disorder - pharmaphorum

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Yahoo Finance

Dec 16, 2024
pulisher
Dec 16, 2024

Wedbush Reiterates Outperform Rating for Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at HC Wainwright - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Goldman Sachs lifts Neurocrine Bio shares target, buy rating on FDA approval - Investing.com Canada

Dec 16, 2024
pulisher
Dec 16, 2024

Launch complexities temper expectations for Neurocrine Bio stock, says BMO Capital - Investing.com Australia

Dec 16, 2024
pulisher
Dec 16, 2024

Geode Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

(NBIX) Technical Data - Stock Traders Daily

Dec 16, 2024
pulisher
Dec 15, 2024

Public Employees Retirement System of Ohio Sells 6,046 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 15, 2024
pulisher
Dec 15, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Barclays PLC - MarketBeat

Dec 15, 2024
pulisher
Dec 15, 2024

Neurocrine wins FDA approval for CAH therapy - MSN

Dec 15, 2024
pulisher
Dec 14, 2024

Neurocrine wins FDA approval for CAH therapy (NBIX:NASDAQ) - Seeking Alpha

Dec 14, 2024
pulisher
Dec 13, 2024

Neurocrine Biosciences to Participate at Investor Conferences in December - The Eastern Progress Online

Dec 13, 2024
pulisher
Dec 13, 2024

US FDA approves Neurocrine Biosciences’ genetic disorder drug - 1470 & 100.3 WMBD

Dec 13, 2024
pulisher
Dec 13, 2024

Neurocrine's CRENESSITY Makes History: First New CAH Treatment in 70 Years Gets FDA Approval - StockTitan

Dec 13, 2024
pulisher
Dec 13, 2024

US FDA approves Neurocrine Biosciences' genetic disorder drug - Reuters.com

Dec 13, 2024
pulisher
Dec 13, 2024

Virtu Financial LLC Invests $1.99 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Dec 13, 2024

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$15.49
price up icon 0.78%
$12.49
price down icon 0.24%
$84.00
price up icon 0.66%
$91.01
price up icon 1.93%
$11.86
price up icon 1.98%
Cap:     |  Volume (24h):